Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Janssen Withdraws EU App for IV Administered Simponi

By Drug Discovery Trends Editor | May 19, 2014

Janssen Biologics B.V. announced that the company has withdrawn its application seeking a change to the Marketing Authorization for Simponi (golimumab) to add a new pharmaceutical form of intravenous (IV) administration for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). Janssen Biologics informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of its decision following receipt of an assessment report that indicated additional clinical data were required to further evaluate the risk to benefit profile of the I.V. formulation. 
 
“We have elected to withdraw our application seeking approval of Simponi I.V. in the European Union as we are unable at this time to provide additional clinical data beyond the pivotal Phase 3 results included in the current submission,” said Newman Yeilding, head of immunology development, Janssen Research & Development, LLC. “While we are disappointed that we will be unable to pursue the approval of Simponi I.V. as a treatment for moderately to severely active rheumatoid arthritis in the European Union, we are confident that the Phase 3 data accumulated through the Simponi I.V. clinical development program demonstrate a positive risk to benefit profile for this anti-tumor necrosis factor (TNF)-alpha therapy.”
 
The withdrawal of the Simponi IV application in the European Union (EU) has no impact on Simponi subcutaneous or intravenous formulations in approved indications worldwide and has no consequences on ongoing clinical trials.
 
Date: May 19, 2014
Source: Janssen
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE